STOCK TITAN

Lexeo Therapeutics: OrbiMed reports 3.9% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. (LXEO) is the issuer named in an amended ownership report: OrbiMed Advisors LLC reported beneficial ownership of 3,203,050 shares, or 3.9%, with shared voting and dispositive power. OrbiMed Capital LLC reported zero shares and 0.0%. The reporting persons stated they hold the 3.9% position on behalf of others entitled to dividends or sale proceeds. The firms exercise voting and investment power through a management committee comprising Carl L. Gordon, W. Carter Neild and Geoffrey C. Hsu, each of whom disclaims beneficial ownership.

Beneficial ownership 3,203,050 shares OrbiMed Advisors LLC
Percentage of class 3.9% OrbiMed Advisors LLC
Beneficial ownership 0 shares OrbiMed Capital LLC; 0.0% of the class
beneficially owned regulatory
"Aggregate amount beneficially owned: 3,203,050"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting power regulatory
"Shared voting power: 3,203,050"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared dispositive power: 3,203,050"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LXEO shares did OrbiMed Advisors report owning?

OrbiMed Advisors LLC reported beneficial ownership of 3,203,050 shares of LXEO common stock, equal to 3.9%, with shared voting and dispositive power. OrbiMed Capital LLC reported zero shares and 0.0%. The reporting persons stated they hold the shares on behalf of others entitled to dividends or proceeds from sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





52886X107

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



OrbiMed Advisors LLC
Signature:/s/ Carl L. Gordon
Name/Title:Carl L. Gordon / Member
Date:11/16/2026
OrbiMed Capital LLC
Signature:/s/ Carl L. Gordon
Name/Title:Carl L. Gordon / Member
Date:11/16/2026

Keep reading